Identifying Modifiable Predictors of Long‐Term Survival in Liver Transplant Recipients With Diabetes Mellitus Using Machine Learning

Angeline Yasodhara, Victor Dong, Amirhossein Azhie, Anna Goldenberg, Mamatha Bhat – 28 October 2020 – Diabetes mellitus (DM) significantly impacts long‐term survival after liver transplantation (LT). We identified survival factors for LT recipients who had DM to inform preventive care using machine‐learning analysis. We analyzed risk factors for mortality in patients from across the United States using the Scientific Registry of Transplant Recipients (SRTR). Patients had undergone LT from 1987 to 2019, with a follow‐up of 6.47 years (standard deviation [SD] 5.95).

The Impact of Dabigatran Treatment on Sinusoidal Protection Against Hepatic Ischemia/Reperfusion Injury in Mice

Daisuke Noguchi, Naohisa Kuriyama, Taemi Hibi, Koki Maeda, Toru Shinkai, Kazuyuki Gyoten, Aoi Hayasaki, Takehiro Fujii, Yusuke Iizawa, Akihiro Tanemura, Yasuhiro Murata, Masashi Kishiwada, Hiroyuki Sakurai, Shugo Mizuno – 27 October 2020 – Thrombin is a key player in the coagulation cascade, and it is attracting much attention as a promotor of cellular injured signaling. In ischemia/reperfusion injury (IRI), which is a severe complication of liver transplantation, thrombin may also promote tissue damage.

NAFLD: Reporting Histologic Findings in Clinical Practice

Elizabeth M. Brunt, David E. Kleiner, Danielle H. Carpenter, Mary Rinella, Stephen A. Harrison, Rohit Loomba, Zobair Younossi, Brent A. Neuschwander‐Tetri, Arun J. Sanyal, for the American Association for the Study of Liver Diseases NASH Task Force – 27 October 2020 – The role of liver biopsy in NASH has evolved along with the increased recognition of the significance of this disease, and the unmet medical need it presents. Drug development and clinical trials are rapidly growing, as are noninvasive tests for markers of steatosis, inflammation, injury, and fibrosis.

Liver Transplantation Using Hepatitis C Virus–Viremic Donors Into Hepatitis C Virus–Aviremic Recipients as Standard of Care

Humberto Bohorquez, Emily Bugeaud, Natalie Bzowej, Jennifer Scheuermann, Jonathan Hand, David Bruce, Ian Carmody, Ari Cohen, Shobha Joshi, John Seal, Dennis Sonnier, George Therapondos, Nigel Girgrah, Stephanie Anders, George E. Loss – 24 October 2020 – Liver transplantation (LT) using allografts from hepatitis C virus (HCV)‐viremic/nucleic acid testing–positive donors’ (DNAT+) organs into HCV‐aviremic recipients (rHCV−) has been limited owing to nearly universal HCV transmission and concerns regarding availability, safety, and efficacy post‐LT with direct‐acting antiviral (DAA) therapy.

Subscribe to